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S180 Oral Presentations23of 25 patients (92%), seeTable 1 for patient data summary. In order
to gain insight into themechanismof this enhancedmobilization, a pi-
lot study investigating gene expression analysis was performed on
CD341 cells purified from frozen control apheresis samples, compar-
ing samples from Vel –mob (n5 7)vs. G-CSF1 CTX(n5 8). A sig-
nificant change in the expression of genes associated with the
following canonical pathways was observed: docosahexaenoic acid sig-
naling, angiopoietin signaling and the molecular mechanisms of can-
cer. In relationship to SDF-1 signaling, there was a 1.44 fold increase
(p# 0.05) inCXCR4mRNA isolated fromCD341 cells in pts treated
with vel-mob when compared to CD341 cells isolated fromGCSF1
CTX treated pts. SDF-1 peripheral blood plasma levels were then
measured in vel-mob treated pts (n 5 7) and compared to the levels
in GCSF alone (n 5 8) treated pts. The mean SDF-1 level in vel-
mob treated pts was significantly decreased (p 5 0.0012) when com-
pared to GCSF alone treated pts (1319 pg/ml vs 2225 pg/ml). Vel-
mob is a novel mobilization regimen that produces very high and pre-
dictable CD341 yields. Vel-mob modulates SDF-1 protein levels in
plasma, CXCR4 gene expression in CD341 cells. We have also iden-
tified important canonical pathways that may be associated with im-
proved mobilization.PEDIATRIC DISORDERS
72
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Rationale:The post transplant infusion of donor lymphocytes (DLI)
has been used to increase alloreactivity against residual
host hematopoiesis in malignant diseases after stem cell transplanta-
tion (SCT).DLI can treat impending rejection, prevent relapse in the
face of decreasing donor chimerism or even treat overt relapse in
some forms of leukemia. However the risk of inducing GVHD after
DLI has limited its use after allogeneic SCT for non malignant
disorders such as primary immunodeficiency diseases (PID).
Methods: PID patients with decreasing donor chimerism despite dis-
continuation of immunosuppression were treated with DLI. The ini-
tial dose of CD31 cells per kg body weight was up to 5*105 for
matched sibling donors (MSD), 1*105 for matched unrelated donors
(MUD) and 2.5*104 for haploidentical family donors (MMFD) in
the absence of GVHD. Patients were to receive additional DLI at 4-
6 week intervals in increasing doses until either GVHD or a stabiliza-
tion/reversal of mixed chimerism was observed.
Results: Ten patients (1 XLP, 2 SCID, 7 WAS) experienced de-
creasing donor chimerism at a median of 94 days (range 62-180
days) after myeloablative (n 5 8, non-SCID) or reduced intensity
(n 5 2, SCID) conditioning SCT from MSD (n 5 1), MUD (n 5
7) or MMFD (n 5 2). None of the patients had had pretransplant
maternal engraftment. They received DLI from their original do-
nors at a median of 120 days (78-366) after SCT. At a median follow
up of 779 days (41-3807) after first DLI and amedian of 5DLI (2-14)
we observed a stabilization of mixed chimerism in 5 patients and im-
provement in 5. None experienced complete rejection or returned to
full donor chimerism. Of note, none of the patients experienced
GVHD of any grade.
Conclusion: DLI after SCT for PID is feasible and may be able to
halt impending rejection. This observation may be especially impor-
tant in the light of an increasing use of reduced intensity condition-
ing regimes with presumably a higher incidence of graft failure and
the fact that many PID can be considered cured even with stable,
low level donor chimerism. We propose a graded dosing regimen
of CD31 cells depending on donor/recipient HLA disparity to min-
imize the risk for DLI induced GVHD, which appeared to be safe
and effective in our patients.73
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Background: Therapeutic drug monitoring (TDM) guided dosing
of busulfan is associated with higher event free survival rates due
to less graft-failure/relapses and lower toxicity in hematological
stem cell transplantation (HSCT). The observed differences in
plasma exposures of intravenously administered busulfan to children
may be related with age, or diseases like immune deficiencies. The
question is whether a more predictable exposure can be obtained
by individualization of busulfan dosing in pediatric HSCT. This
study aims to predict the growth related developmental changes in
the pharmacokinetics (PK) of busulfan, using an extensive covariate
analysis, in order to design an individualized dosing regimen.
Methods: In this retrospective multicentre study, 245 patients were
included, ranging between 1 month and 26 years of age. All patients
intravenously received busulfan-based conditioning combined with
therapeutic drug monitoring (TDM). Data were gathered from
four pediatric centers. Demographics, diagnosis, concomitant med-
ication, hematological and clinical chemistry parameters were used
as covariates, using linear and allometric correlations. NONMEM
was used for data and covariates analysis.
Results: Bodyweight significantly influenced the PK of busulfan in
a nonlinear relation. The other evaluated covariates did not influence
the pharmacokinetic parameters. An allometric scaling method was
used to estimate the clearance of each individual, resulting in
the function for clearance: 2.94L/h *(BWi/15kg)
exp a. Based on
objective function, diagnostics and root mean square error, the
model with ‘‘exp a’’ as one single exponent was inferior compared
to a bodyweight-dependent exponent, with a function; exp a 5
1.96*BW20.234. This model resulted in a scaling exponent of 1.51
in neonates (BW 3-5 kg) decreasing to 0.65 in young adults (BW
80-109 kg). The volume of distribution was allometrically scaled
with one single exponent of 0.87. Based upon this final model
a new dosing regimen was designed to obtain an AUC of 95 mg*h/
L for myeloablative or 45 mg*h/L for non-myeloablative regimens.
Conclusions: This population PK model for busulfan in patients
ranging between 1 month and 26 years of age, describes the PK pa-
rameters of busulfan using a continuous non-linear function depend-
ing on bodyweight. The model-derived individualized dosing
regimen, which is expected to lead to a more predictable exposure
of busulfan in each child, will be prospectively evaluated.74
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Myeloablative (MA) SCT is curative of SCD, and children with
stable donor engraftment no longer experience SCD symptoms
(Walters et al, BBMT 2009), but quality of life may be diminished
by MA SCT related organ toxicity. RTC regimens may potentially
enhance preservation of organ function in patients with SCD. Be-
tween 8/27/2004 and 3/2/10, 18 (16M: 2F) patients with symptom-
atic SCD underwent RTC SCT. Conditioning was Busulfan (4mg/
kg  4d # 4 yrs and 12.8mg/kg  4d . 4 yrs), Fludarabine
(30mg/m2  6d), and Alemtuzumab (2mg/m2  1d, 6mg/m2  2d,
and 20mg/m2  2d). Donor sources: 8-6/6 related bone marrow,
2-6/6 related cord blood (CB), 1-6/6 unrelated CB, 4-5/6 unrelated
